<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemoprevention strategies in prostate cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemoprevention strategies in prostate cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chemoprevention strategies in prostate cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A Oliver Sartor, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Robert Lee, MD, MS, MEd</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prostate cancer is the second most common cancer in males worldwide, according to data from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fgco.iarc.fr%2Ftoday%2Fhome&amp;token=o1j24x8yqbCigYycIC6ni4B7VDe7Hz17hJNfy5f8gT3%2F1GKAFN45f%2BlZyQqB2Xd7&amp;TOPIC_ID=6949" target="_blank">GLOBOCAN</a> database. In the United States, there were an estimated 191,930 cases and 33,330 deaths from prostate cancer in 2020 [<a href="#rid1">1</a>].</p><p>In the United States, the incidence of prostate cancer detection dramatically rose in the early 1990s in conjunction with the increasing utilization of prostate-specific antigen (PSA) screening. After an initial peak, incidence rates fell, but they have persisted at a rate nearly twice that recorded in the pre-PSA era, suggesting that many cases are clinically indolent and would never have become clinically apparent. Despite the increase in diagnosis of early stage prostate cancer, the impact of earlier treatment on survival remains to be proven.</p><p>The implementation of the United States Preventative Services Task Force (USPSTF)<strong> </strong>guidelines assigning a recommendation level of D has reduced the number of males seeking early detection, as well as reduced the number of transrectal ultrasound (TRUS) biopsies. Some centers have reported an increase in males with more aggressive and advanced disease.</p><p>The high incidence of prostate cancer, its associated morbidity and mortality, the complications associated with its treatment, and a partial understanding of its biologic basis have led to a focus on chemoprevention strategies. The most extensive data come from the use of 5-alpha reductase (5-AR) inhibitors; other classes of agents are also being explored.</p><p>The rationale for chemoprevention, the results with 5-AR inhibitors, and the more limited data with other approaches are presented here. Screening for prostate cancer, an alternative approach that focuses on early detection to decrease morbidity and mortality, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">"Screening for prostate cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>Three factors have contributed to the rationale for prostate cancer chemoprevention in males: the long latency period between the initial evidence of prostate cancer and the development of overt or fatal disease, the androgen dependency of these tumors, and the availability of intermediate endpoints for use in clinical trials.</p><p class="headingAnchor" id="H3"><span class="h2">Long latency period</span><span class="headingEndMark"> — </span>The marked discrepancy between the autopsy prevalence of occult prostate cancer and the incidence of clinically manifest disease indicates that there is a long latency phase and significant heterogeneity in the rate of progression of early neoplastic lesions. Progression to invasive cancer in males with high-grade prostatic intraepithelial neoplasia (PIN) may take 10 years or more. (See  <a class="medical medical_review" href="/z/d/html/6925.html" rel="external">"Precancerous lesions of the prostate: Pathology and clinical implications", section on 'Prostatic intraepithelial neoplasia'</a>.)</p><p>As a result, chemoprevention strategies that do not reverse the premalignant condition but merely delay its progression to invasive cancer may be sufficient to improve survival or avoid the complications of the disease or its treatment [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Androgen dependency</span><span class="headingEndMark"> — </span>Direct or indirect androgenic influences are important in the malignant transformation of prostatic tissue. Males with 5-alpha reductase (5-AR) deficiency (the enzyme that converts testosterone to dihydrotestosterone [DHT], the most active androgen in the prostate) do not develop prostate cancer [<a href="#rid4">4</a>]. The precursor lesion, high-grade PIN, is also hormonally dependent. The atrophy and apoptotic changes that occur with androgen deprivation in normal and hyperplastic prostatic epithelium and in invasive cancers are also observed in PIN [<a href="#rid5">5</a>].</p><p>These data suggest that interference with normal androgen balance may affect prostate cancer incidence. Medical therapies directed at hormonal manipulation include estrogens, antiandrogens, gonadotropin-releasing hormone (GnRH) agonists, and 5-AR inhibitors. Most of these therapies are not candidates for use as chemopreventive agents because of potential side effects. The use of 5-AR inhibitors or antiandrogens that block the androgen receptor may be associated with fewer side effects because serum testosterone levels remain unaltered. (See  <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Clinical trials biomarkers</span><span class="headingEndMark"> — </span>Development of chemopreventive agent(s) may be facilitated by the availability of biomarkers that may predict the subsequent development of prostate cancer or that can be used to define its progression and, thus, serve as intermediate endpoints for clinical trials.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostatic intraepithelial neoplasia</strong> – PIN represents a spectrum of dysplastic changes that are limited to prostatic acini and do not invade the basement membrane. High-grade PIN is thought to be associated with an increased prostate cancer risk. The pathologic features of PIN and its relationship to cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6925.html" rel="external">"Precancerous lesions of the prostate: Pathology and clinical implications", section on 'Prostatic intraepithelial neoplasia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate-specific antigen</strong> – Changes in serum prostate-specific antigen (PSA) concentration and its association with prostate cancer suggest that serum PSA may be a useful biomarker and that defined changes could act as intermediate endpoints in the setting of chemoprevention trials. However, serum PSA is also secreted by normal prostate tissue, and as an androgen-regulated gene, levels are incompletely correlated with tumor burden. (See  <a class="medical medical_review" href="/z/d/html/7568.html" rel="external">"Measurement of prostate-specific antigen"</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">5-ALPHA REDUCTASE INHIBITORS</span><span class="headingEndMark"> — </span>The 5-alpha reductase (5-AR) inhibitors <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> and <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> are used primarily for treatment of benign prostatic hyperplasia. They improve lower urinary tract symptoms by blocking the conversion of testosterone into the more potent androgen dihydrotestosterone (DHT).</p><p>Androgens are a key driver of prostate carcinogenesis. There are data from at least two randomized trials that support a reduced risk of prostate cancer in males receiving 5-AR inhibitors; however, no survival benefit has been shown in either trial, and both raised concerns about a possible increased risk of high-grade prostate cancer. The US Food and Drug Administration (FDA) has not approved the use of these agents for prostate cancer prevention, and in 2011, it issued a safety warning about the elevated risk of high-grade cancers, stating that one additional high-grade cancer would occur for every three to four lower grade cancers that would be prevented [<a href="#rid6">6</a>]. Although a subsequent analysis of data from the Prostate Cancer Prevention Trial (PCPT) found that <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> increased the detection rate of high-grade prostate cancer by shrinking the prostate, thereby introducing a potential detection bias [<a href="#rid7">7</a>], and the clinical significance of this finding remains unclear, concerns remain, and these drugs are not widely used for prostate cancer chemoprevention.</p><p>For most males, we suggest not using chemopreventive therapy with a 5-AR inhibitor. However, chemopreventive therapy with a 5-AR inhibitor in conjunction with monitoring serum prostate-specific antigen (PSA) may be appropriate for those who place a higher value on preventing cancer than on the side effects associated with such therapy and the uncertainties as to benefits and risks.</p><p>Guidelines from an expert panel of the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) identified key issues that clinicians and males should discuss when deciding whether or not to use a 5-AR inhibitor for prostate cancer chemoprevention [<a href="#rid8">8,9</a>]. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>5-AR inhibitors decrease, but do not eliminate, the risk of prostate cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An elevated rate of high-grade prostate cancers has been observed in patients taking <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> [<a href="#rid10">10</a>] and <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> [<a href="#rid11">11</a>], although the significance of these observations remain unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is scant information about whether these agents decrease the risk of death from prostate cancer or affect overall survival. In at least one analysis using data from 89,227 males diagnosed with prostate cancer between 2007 and 2016 derived from the Prostate Cancer Data Base Sweden, the risk of prostate cancer death for all cases, including males with high-risk disease, was similar among 5-AR inhibitor users and nonusers [<a href="#rid12">12</a>]. The median years of follow-up for these males ranged from 5.2 to 6.7 years. There is no information about the effects of use beyond seven years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Side effects of these agents include gynecomastia, decreased libido, erectile dysfunction, and decreased ejaculate volume. At the same time, these agents may decrease urinary tract symptoms due to benign prostatic hyperplasia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>5-AR inhibitors reduce serum PSA levels by an average of 50 percent, which can affect the use of serum PSA for prostate cancer detection in males treated with these agents [<a href="#rid13">13-15</a>].</p><p></p><p class="headingAnchor" id="H98462141"><span class="h2">Finasteride: PCPT</span><span class="headingEndMark"> — </span>In the Prostate Cancer Prevention Trial (PCPT), 18,882 males were randomly assigned to <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (5 mg/day) or placebo between 1994 and 1997 [<a href="#rid10">10,16</a>].</p><p>Males were considered at elevated risk of prostate cancer based on age ≥55 years, African-American ethnicity, or having a first-degree relative with prostate cancer. All had a normal digital rectal examination (DRE) and a serum PSA ≤3 ng/mL.</p><p>Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (which decreases the serum PSA by approximately 50 percent), was ≥4 ng/mL or if the DRE became abnormal. In addition, all males were offered a prostate biopsy at the end of study (seven years).</p><p>The PCPT was closed early because the primary study endpoint (ie, a decrease in the prevalence of biopsy-proven prostate cancer in the <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> population compared with placebo) was met. The initial analysis found a 25 percent decrease in the incidence of prostate cancer with seven years of finasteride, but there was also an observed increase in the absolute number and proportion of high-grade prostate cancers (ie, Gleason score ≥7) [<a href="#rid10">10</a>].</p><p>A long-term follow-up of this study (up to 18 years of follow-up), which included the identification of 187 additional cases of prostate cancer, analyzed overall survival data through October 2011 [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>There was a statistically significant decrease in the incidence of prostate cancer in males assigned to <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> compared with placebo (10.5 versus 14.9 percent, relative risk [RR] 0.70, 95% CI 0.65-0.76).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There remained a small but statistically significant increase in the risk of high-grade prostate cancer (Gleason score ≥7) with <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (3.5 versus 3.0 percent, RR 1.17, 95% CI 1.00-1.37, p = 0.05).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 15-year overall survival rates for the <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> and placebo groups were 78.0 and 78.2 percent, respectively (unadjusted hazard ratio [HR] 1.02, 95% CI 0.97-1.08).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among males who subsequently developed prostate cancer, there were no significant differences in the 10-year overall survival rates in males assigned to <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> or placebo. For males with low-grade prostate cancer (Gleason score ≤6), the 10-year overall survival rates were 83.0 and 80.9 percent, respectively, and for those with high-grade prostate cancer (Gleason score ≥7), the 10-year overall survival rates were 73.0 and 73.6 percent, respectively.</p><p></p><p>At 20+ years of follow-up, the HR for prostate cancer-specific death with <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> versus placebo was 0.75 (95% CI 0.50-1.12) [<a href="#rid17">17</a>].</p><p>Long-term benefit after discontinuation of <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> was also explored in a subsequent analysis linking PCPT clinical records to the participants' Medicare claims data [<a href="#rid18">18</a>]. Throughout the entire course of follow-up (median 16 years), finasteride participants maintained a 21 percent reduction in the risk of prostate cancer (HR 0.79, 95% CI 0.74-0.84). However, the protective effect was significant only through year 7.5 (HR 0.71, 95% CI 0.66-0.77) and not afterwards (HR 1.10, 95% CI 0.96-1.26).</p><p>The observed increase in the number of patients with high-grade cancers dampened enthusiasm for the use of <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> as a chemopreventive agent [<a href="#rid19">19</a>], even though several subsequent analyses suggested that the observed increase in high-grade lesions did not represent a true alteration in the biology of the disease and, instead, likely indicated detection bias attributed to the fact that finasteride shrinks the prostate, thereby increasing the detection of high-grade disease [<a href="#rid20">20-24</a>].</p><p>Nevertheless, in our view, the absence of a difference in overall or prostate cancer-specific survival with longer follow-up provides clear evidence that an increase in high-grade prostate cancer is not a major factor affecting overall survival and that chemoprevention using <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> may safely decrease the incidence of low-grade prostate cancers [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Dutasteride: REDUCE trial</span><span class="headingEndMark"> — </span>The effects of <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> on the incidence of prostate cancer were evaluated in the double-blind Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, in which 8336 males were randomly assigned to dutasteride (0.5 mg/day for four years) or placebo [<a href="#rid11">11</a>]. All males were considered at increased risk for prostate cancer based on age and serum PSA level, and all had a single negative prostate biopsy within six months prior to protocol entry. Males 50 to less than 60 years of age had a baseline serum PSA of 2.5 to 10 ng/mL, while those 60 to 75 years of age had a PSA 3 to 10 ng/mL. The protocol called for repeat 10-core biopsies at two and four years after treatment initiation.</p><p>Key findings included:</p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of prostate cancer was significantly reduced in males assigned to <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> compared with placebo (25.1 versus 19.9 percent, RR reduction 23 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The decrease in incidence was limited to cancers with a Gleason score of 5 or 6, which constituted 70 percent of all cases diagnosed. There was no statistically significant reduction in risk of prostate cancer with Gleason scores of 7 to 10. Overall, in years 1 through 4, there were 220 Gleason score 7 to 10 tumors diagnosed in the <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> group and 233 in the placebo group, a difference that was not significant (6.7 versus 6.8 percent, p = 0.81). Mortality rates were similar in both groups, and no deaths were attributed to prostate cancer in either group.</p><p></p><p class="headingAnchor" id="H1545487671"><span class="h2">Other data</span><span class="headingEndMark"> — </span>Additional data on the impact of 5-AR inhibitors on the risk of prostate cancer are available from a Swedish population-based cohort study of all males over the age of 40 who had at least one PSA test in Stockholm County between 2007 and 2018 [<a href="#rid25">25</a>]. Of the 349,152 in the cohort, 26,190 had been prescribed a 5-AR inhibitor at some time during the study period. With a median follow-up of 8.2 years, prostate cancer was diagnosed in 0.4 versus 4.1 percent of the individuals treated with versus without a 5-AR inhibitor, and despite the association of 5-AR inhibitor use with higher PSA levels, larger prostates, higher Gleason score, and a higher TNM stage at diagnosis, treatment with a 5-AR inhibitor decreased the risk of prostate cancer mortality, with a larger effect seen with longer duration of exposure. With 0.1 to 2 years of exposure, the adjusted HR was 0.89 (95% CI 0.0.64-1.25); at 2 to 4 years, adjusted HR was 0.54 (95% CI 0.37-0.78); at 4 to 6 years, adjusted HR was 0.72 (95% CI 0.52-1.01); at 6 to 8 years, adjusted HR was 0.51 (95% CI 0.33-0.79); &gt;8 years, HR was 0.44 (95% CI 0.27-0.74). (See <a class="local">'Finasteride: PCPT'</a> above.)</p><p>These data provide some reassurance that treatment with a 5-AR inhibitor for lower urinary tract symptoms in males is safe with regard to prostate cancer risk. An important point is that, because 5-AR inhibitors reduce the serum concentration of PSA by approximately 50 percent, clinicians should use adjusted levels of PSA when screening males who are receiving these drugs for prostate cancer; otherwise, the diagnosis may be delayed and result in worse cancer-specific outcomes [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/7568.html" rel="external">"Measurement of prostate-specific antigen", section on 'Medications'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">OTHER AGENTS</span><span class="headingEndMark"> — </span>A number of other agents are being studied to prevent prostate cancer. All of them remain experimental.</p><p class="headingAnchor" id="H12994978"><span class="h2">Statins</span><span class="headingEndMark"> — </span>Multiple studies have looked at the relationship between statin use and prostate cancer. Although the data regarding an impact on the incidence are equivocal, epidemiologic findings suggest that statin use may have a beneficial effect on the risk of prostate cancer progression and death. Prospective trials are needed to validate the importance of these agents. (See  <a class="medical medical_review" href="/z/d/html/6893.html" rel="external">"Overview of cancer prevention", section on 'Statins'</a>.)</p><p class="headingAnchor" id="H73767222"><span class="h2">Metformin</span><span class="headingEndMark"> — </span>Epidemiologic studies have suggested that diabetic patients using <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> have a decreased incidence of a variety of malignancies other than prostate cancer compared with those not being treated with metformin. No prospective trials support these observations, and caution is advised. (See  <a class="medical medical_review" href="/z/d/html/6893.html" rel="external">"Overview of cancer prevention", section on 'Metformin'</a>.)</p><p><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> does not appear to have a substantial impact on the overall incidence of prostate cancer. As an example, in a study of over 119,000 males ≥66 years old with incident diabetes, prostate cancer was subsequently diagnosed in 5306 [<a href="#rid27">27</a>]. There was no difference in the risk of prostate cancer (adjusted odds ratio [OR] 1.03, 95% CI 0.96-1.1).</p><p><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> may have an effect on the progression of disease in diabetic patients with prostate cancer. In a study that included 3837 patients older than 66 years with a new diagnosis of diabetes who were subsequently diagnosed with prostate cancer, prostate cancer-specific mortality was significantly decreased in those treated with metformin [<a href="#rid28">28</a>]. The decrease in mortality with metformin use was proportional to the cumulative duration of metformin use (hazard ratio [HR] for prostate cancer-specific mortality 0.76 for each additional six months of use of metformin). This effect was not observed with other diabetic medications. These observations require confirmation.</p><p class="headingAnchor" id="H13"><span class="h2">Vitamins and micronutrients</span><span class="headingEndMark"> — </span>The available data on vitamins and dietary supplements for chemoprevention are extensive and difficult to interpret. Currently, available data have not established a role for any of these agents in the prevention of prostate cancer.</p><p>The most extensively studied agents are <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> (alpha-tocopherol) and <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>.</p><p class="headingAnchor" id="H14"><span class="h3">Vitamin E</span><span class="headingEndMark"> — </span>Males should avoid <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> supplementation at doses that exceed dietary intakes. Current evidence does not support a role for vitamin E supplementation in the prevention or treatment of cancers, cardiovascular disease, dementia, or infection. (See  <a class="medical medical_review" href="/z/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Vitamin E'</a> and  <a class="medical medical_review" href="/z/d/html/2582.html" rel="external">"Overview of vitamin E"</a>.)</p><p>Two randomized trials, the alpha-tocopherol <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a> (ATBC) intervention trial [<a href="#rid29">29-31</a>] and the Heart Outcomes Prevention Evaluation – The Ongoing Outcomes (HOPE-TOO) trial [<a href="#rid32">32</a>], provided conflicting evidence regarding the incidence of prostate cancer as a secondary outcome.</p><p>Two randomized trials specifically designed to study the impact of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> on prostate cancer incidence failed to provide any evidence supporting a chemopreventive role:</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">Selenium</a> and <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">Vitamin E</a> Cancer Prevention Trial (SELECT) was designed to study the role of selenium and vitamin E as agents to decrease the incidence of prostate cancer. In this trial, 35,533 males were randomly assigned to selenium (200 mcg/day), vitamin E (400 international units/day), both, or neither with appropriate placebos [<a href="#rid33">33</a>]. This trial was stopped in October 2008 after an independent data safety monitoring committee found no evidence of a decrease in the incidence of prostate cancer. Dietary supplementation with vitamin E significantly <strong>increased</strong> the incidence of prostate cancer, and there were nonsignificant increases with selenium and the combination of vitamin E plus selenium compared with placebo (HR for developing prostate cancer 1.17, 1.09, and 1.05, respectively) [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Physicians' Health Study II (PHS II) was a double-blind, placebo-controlled trial in which 14,641 male clinicians ages 55 years and older were randomly assigned to <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a>, <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, ascorbic acid, and/or a multivitamin [<a href="#rid36">36</a>]. One of the primary endpoints of this study was the prevention of prostate cancer. The incidence of prostate cancer was not significantly reduced with any of the agents, including vitamin E (HR 0.97, 95% CI 0.85-1.09) [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h3">Selenium</span><span class="headingEndMark"> — </span>The relationship between prostate cancer and <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> intake and level is complex. (See  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Selenium and vitamin E'</a>.)</p><p>However, there is no evidence to support a chemopreventive effect from <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> supplementation [<a href="#rid35">35</a>]. The effect of selenium supplementation was directly evaluated in SELECT, which included 35,533 males at risk for prostate cancer. The incidence of prostate cancer was nonsignificantly <strong>increased</strong> with selenium alone or in combination with <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> (HR 1.09 and 1.05, respectively). Further subsequent analyses found that selenium supplementation did not benefit males with low selenium status but increased the risk of high-grade prostate cancer among males with high selenium status [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Vitamin D analogs</span><span class="headingEndMark"> — </span>A link between vitamin D levels and prostate cancer risk has been suggested, mainly based on the association of vitamin D deficiency with epidemiologic risk factors such as age, African-American race, and geographic area of residence [<a href="#rid39">39-46</a>]. Preclinical studies support an antiproliferative, antimetastatic, and differentiating effect of vitamin D and its analogues in prostate cancer, providing a rationale for the consideration of these compounds as potential chemopreventive agents. No prospective trials have confirmed this effect.</p><p class="headingAnchor" id="H17"><span class="h3">Retinoids</span><span class="headingEndMark"> — </span>Retinoids are metabolites and analogs of vitamin A that are required for the proper differentiation of various epithelial tissues, and they play a regulatory role in the activation of cytokines and the extracellular matrix. Chemoprevention trials are ongoing with retinoids in lung cancer, breast cancer, and head and neck cancer. (See  <a class="medical medical_review" href="/z/d/html/3391.html" rel="external">"Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer"</a>.)</p><p>Fenretinide, a synthetic retinoid, has been evaluated in males with prostate cancer in preliminary studies [<a href="#rid47">47-49</a>]. However, these trials have not yielded evidence of activity, and this class of agents is not under active investigation for chemoprevention against prostate cancer.</p><p class="headingAnchor" id="H20"><span class="h2">Dietary factors</span><span class="headingEndMark"> — </span>A number of dietary factors have been analyzed for their association with the risk of prostate cancer. Although information from these studies may be useful in defining new approaches to chemoprevention, none of these has an established role in prostate cancer chemoprevention. (See  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Diet'</a>.)</p><p>Phytoestrogens (flavones, isoflavones, lignans) are naturally occurring plant compounds that have estrogen-like activity. Genistein and daidzein, the predominant isoflavones in human nutrition, are derived mainly from soybeans and other legumes.</p><p>Phytoestrogens may reduce prostate cancer risk either via their inherent estrogenic properties (which favorably alter the hormonal milieu) or by inhibition of 5-alpha reductase (5-AR), which decreases concentrations of the more prostate-active androgen dihydrotestosterone (DHT). The higher intake of soy products among Asian males has been hypothesized to be one reason for their generally lower incidence of prostate cancer.</p><p>The most provocative data linking soy or phytoestrogen exposure to a reduced prostate cancer risk come from animal studies [<a href="#rid50">50-52</a>]. In humans, most of the case-control studies have shown a modest protective benefit of soy on prostate cancer risk. (See  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Soy intake'</a>.)</p><p>In one randomized trial, 310 males with high-grade prostatic intraepithelial neoplasia were randomly assigned to a combination of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, soy, and <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> or to placebo. There was no evidence that the combination prevented progression to prostate cancer [<a href="#rid53">53</a>]. Several other randomized, placebo-controlled clinical trials evaluating soy protein in males with treated prostate cancer who are at high risk for recurrence are ongoing.</p><p class="headingAnchor" id="H1823257973"><span class="h1">LIFESTYLE FACTORS</span><span class="headingEndMark"> — </span>Potentially modifiable lifestyle factors, particularly smoking and obesity, have been shown to increase the risk of prostate cancer, particularly for aggressive or advanced disease [<a href="#rid54">54</a>]. Factors such as diet that are associated with good cardiovascular health may also contribute to preventing the initiation and progression of prostate cancer. (See  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Cigarette smoking'</a> and  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Obesity'</a> and  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The high incidence of prostate cancer, its associated morbidity and mortality, and its hormone dependency all have made prostate cancer an important target for chemopreventive strategies. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In randomized trials, 5-alpha-reductase (5-AR) inhibitors have been shown to significantly decrease the incidence of prostate cancer. However, no trials have demonstrated an impact on prostate cancer mortality. With long-term follow-up of the randomized trials, there is no clear evidence that these agents increase the incidence of higher grade prostate cancer or are associated with increased prostate cancer-specific mortality. (See <a class="local">'5-Alpha reductase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1">The potential side effects (gynecomastia, decreased libido, erectile dysfunction), benefits (decreased symptoms from benign prostatic hyperplasia), and areas of persisting uncertainty (long-term side effects) should be explained to males considering chemopreventive therapy. For most males, we suggest not using chemopreventive therapy with a 5-AR inhibitor (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). However, chemopreventive therapy with a 5-AR inhibitor in conjunction with monitoring serum prostate-specific antigen (PSA; with levels adjusted for the use of the 5-AR inhibitor) may be appropriate for those who consider preventing cancer more important than the side effects associated with such therapy. (See <a class="local">'5-Alpha reductase inhibitors'</a> above.)</p><p></p><p>There are no data that support the use of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>, or other agents for routine use, and such agents remain experimental. (See <a class="local">'Other agents'</a> above.)</p><p class="headingAnchor" id="H4001364934"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge E David Crawford, MD, who contributed to an earlier version of this topic review.</p><p>We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7.</a></li><li><a class="nounderline abstract_t">Gaudin PB, Sesterhenn IA, Wojno KJ, et al. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 1997; 49:558.</a></li><li><a class="nounderline abstract_t">Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150:379.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213.</a></li><li><a class="nounderline abstract_t">Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122:552.</a></li><li><a class="nounderline abstract_t">Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365:97.</a></li><li><a class="nounderline abstract_t">Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98:1128.</a></li><li><a class="nounderline abstract_t">Kramer BS, Hagerty KL, Justman S, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009; 27:1502.</a></li><li><a class="nounderline abstract_t">Kramer BS, Hagerty KL, Justman S, et al. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009; 181:1642.</a></li><li><a class="nounderline abstract_t">Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215.</a></li><li><a class="nounderline abstract_t">Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192.</a></li><li><a class="nounderline abstract_t">Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death. J Urol 2020; 204:714.</a></li><li><a class="nounderline abstract_t">Trump DL, Waldstreicher JA, Kolvenbag G, et al. Androgen antagonists: Potential role in prostate cancer prevention. Urology 2001; 57:64.</a></li><li><a class="nounderline abstract_t">Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155:3.</a></li><li><a class="nounderline abstract_t">Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006; 175:1657.</a></li><li><a class="nounderline abstract_t">Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013; 369:603.</a></li><li><a class="nounderline abstract_t">Goodman PJ, Tangen CM, Darke AK, et al. Long-Term Effects of Finasteride on Prostate Cancer Mortality. N Engl J Med 2019; 380:393.</a></li><li><a class="nounderline abstract_t">Unger JM, Hershman DL, Till C, et al. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2018; 110:1208.</a></li><li><a class="nounderline abstract_t">Andriole GL, Humphrey PA, Serfling RJ, Grubb RL. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? J Natl Cancer Inst 2007; 99:1355.</a></li><li><a class="nounderline abstract_t">Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99:1366.</a></li><li><a class="nounderline abstract_t">Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99:1375.</a></li><li><a class="nounderline abstract_t">Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) 2008; 1:167.</a></li><li><a class="nounderline abstract_t">Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008; 1:174.</a></li><li><a class="nounderline abstract_t">Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila) 2008; 1:182.</a></li><li><a class="nounderline abstract_t">Björnebo L, Nordström T, Discacciati A, et al. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncol 2022; 8:1019.</a></li><li><a class="nounderline abstract_t">Sarkar RR, Parsons JK, Bryant AK, et al. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Intern Med 2019; 179:812.</a></li><li><a class="nounderline abstract_t">Margel D, Urbach D, Lipscombe LL, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013; 105:1123.</a></li><li><a class="nounderline abstract_t">Margel D, Urbach DR, Lipscombe LL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31:3069.</a></li><li><a class="nounderline abstract_t">Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029.</a></li><li><a class="nounderline abstract_t">Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90:440.</a></li><li><a class="nounderline abstract_t">Virtamo J, Pietinen P, Huttunen JK, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003; 290:476.</a></li><li><a class="nounderline abstract_t">Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338.</a></li><li><a class="nounderline abstract_t">Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005; 97:94.</a></li><li><a class="nounderline abstract_t">Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39.</a></li><li><a class="nounderline abstract_t">Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549.</a></li><li><a class="nounderline abstract_t">Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000; 10:125.</a></li><li><a class="nounderline abstract_t">Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301:52.</a></li><li><a class="nounderline abstract_t">Kristal AR, Darke AK, Morris JS, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 2014; 106:djt456.</a></li><li><a class="nounderline abstract_t">Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10:1307.</a></li><li><a class="nounderline abstract_t">Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2:467.</a></li><li><a class="nounderline abstract_t">Ingles SA, Coetzee GA, Ross RK, et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58:1620.</a></li><li><a class="nounderline abstract_t">Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11:847.</a></li><li><a class="nounderline abstract_t">Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998; 7:385.</a></li><li><a class="nounderline abstract_t">Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998; 9:559.</a></li><li><a class="nounderline abstract_t">Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998; 9:567.</a></li><li><a class="nounderline abstract_t">Lieberman R, Bermejo C, Akaza H, et al. Progress in prostate cancer chemoprevention: modulators of promotion and progression. Urology 2001; 58:835.</a></li><li><a class="nounderline abstract_t">Lotan Y, Xu XC, Shalev M, et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 2000; 18:116.</a></li><li><a class="nounderline abstract_t">Thaller C, Shalev M, Frolov A, et al. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol 2000; 18:3804.</a></li><li><a class="nounderline abstract_t">Urban D, Myers R, Manne U, et al. Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol 1999; 35:429.</a></li><li><a class="nounderline abstract_t">Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 2000; 45:101.</a></li><li><a class="nounderline abstract_t">Bylund A, Zhang JX, Bergh A, et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 2000; 42:304.</a></li><li><a class="nounderline abstract_t">Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21:113.</a></li><li><a class="nounderline abstract_t">Fleshner NE, Kapusta L, Donnelly B, et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol 2011; 29:2386.</a></li><li><a class="nounderline abstract_t">Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014; 15:e484.</a></li></ol></div><div id="topicVersionRevision">Topic 6949 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912902" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer statistics, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9111625" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8326560" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4432067" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2828003" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Activation of programmed cell death in the rat ventral prostate after castration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21675880" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912265" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252137" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249063" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12824459" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The influence of finasteride on the development of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20357281" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of dutasteride on the risk of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243243" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11295597" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Androgen antagonists: Potential role in prostate cancer prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490873" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effect of finasteride on prostate specific antigen: review of available data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16600723" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23944298" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term survival of participants in the prostate cancer prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30673548" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-Term Effects of Finasteride on Prostate Cancer Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29534197" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848666" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848668" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848673" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138952" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138953" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138954" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Estimating rates of true high-grade disease in the prostate cancer prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35587340" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31058923" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23853056" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association between metformin use and risk of prostate cancer and its grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23918942" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127329" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521168" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12876090" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769967" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657339" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066370" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21990298" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691066" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066368" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24563519" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2241107" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8220092" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vitamin D and prostate cancer: a prediagnostic study with stored sera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563471" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association of prostate cancer with vitamin D receptor haplotypes in African-Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11075874" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9610787" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189041" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189042" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11744441" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Progress in prostate cancer chemoprevention: modulators of promotion and progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10623701" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Differential expression of nuclear retinoid receptors in normal and malignant prostates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078493" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325501" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation of biomarker modulation by fenretinide in prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11027408" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679760" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8058523" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Soy intake and cancer risk: a review of the in vitro and in vivo data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21537051" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25281467" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prevention and early detection of prostate cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
